Vanguard Group Inc. Sells 1,327,329 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Vanguard Group Inc. cut its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 10.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 11,715,748 shares of the biopharmaceutical company’s stock after selling 1,327,329 shares during the quarter. Vanguard Group Inc. owned approximately 0.06% of Esperion Therapeutics worth $25,775,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Cibc World Markets Corp purchased a new position in shares of Esperion Therapeutics in the 4th quarter worth approximately $39,000. SJS Investment Consulting Inc. bought a new stake in Esperion Therapeutics during the fourth quarter worth $55,000. Foundations Investment Advisors LLC grew its stake in Esperion Therapeutics by 48.6% in the 4th quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 9,872 shares during the period. J.W. Cole Advisors Inc. bought a new position in Esperion Therapeutics in the 4th quarter valued at $66,000. Finally, SLT Holdings LLC purchased a new stake in shares of Esperion Therapeutics during the 4th quarter valued at $66,000. 47.39% of the stock is owned by institutional investors.

Esperion Therapeutics Stock Down 2.0 %

NASDAQ ESPR opened at $1.00 on Tuesday. The company’s 50 day moving average is $1.56 and its 200-day moving average is $2.02. The firm has a market cap of $197.67 million, a P/E ratio of -1.56 and a beta of 0.86. Esperion Therapeutics, Inc. has a 12-month low of $0.93 and a 12-month high of $3.94.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Cantor Fitzgerald started coverage on shares of Esperion Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price target for the company. The Goldman Sachs Group began coverage on shares of Esperion Therapeutics in a research note on Wednesday, December 18th. They set a “neutral” rating and a $4.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Esperion Therapeutics in a report on Thursday, March 20th. Needham & Company LLC reissued a “buy” rating and set a $5.00 price objective on shares of Esperion Therapeutics in a report on Tuesday, April 8th. Finally, JMP Securities restated a “market outperform” rating and issued a $4.00 target price (down from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $6.58.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.